Kintsugi develops voice-based AI technologies designed to detect signs of mental health conditions from short samples of natural speech. The company’s platform focuses on identifying acoustic patterns associated with depression and anxiety to support earlier and more objective assessment. Its approach treats voice as a scalable digital biomarker that can be captured with minimal effort. Kintsugi positions its technology within clinical screening and digital mental health contexts.

The technology analyzes acoustic and temporal features of speech, such as tone, cadence, and variability, that correlate with emotional and cognitive states. Machine learning models are trained to detect subtle vocal signatures linked to depression and anxiety, even from brief recordings lasting only seconds. This analysis is performed without requiring scripted tasks or lengthy questionnaires. The system emphasizes speed, low friction, and consistency, enabling repeatable assessments over time.

Kintsugi targets mental health screening and diagnostic support for clinicians and healthcare organizations. The platform is intended to complement traditional clinical evaluation rather than replace formal diagnosis. Its focus reflects growing interest in passive, non-invasive biomarkers that can enhance access to and objectivity in mental health assessment.

Kintsugi closed operations in 2026, turning their work into an open-source repository.